Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls - PubMed (original) (raw)

Review

. 2013 Nov;38(12):2327-37.

doi: 10.1038/npp.2013.152. Epub 2013 Jun 24.

Affiliations

Review

Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls

Mary Falcone et al. Neuropsychopharmacology. 2013 Nov.

Abstract

The integration of research on neuroimaging and pharmacogenetics holds promise for improving treatment for neuropsychiatric conditions. Neuroimaging may provide a more sensitive early measure of treatment response in genetically defined patient groups, and could facilitate development of novel therapies based on an improved understanding of pathogenic mechanisms underlying pharmacogenetic associations. This review summarizes progress in efforts to incorporate neuroimaging into genetics and treatment research on major psychiatric disorders, such as schizophrenia, major depressive disorder, bipolar disorder, attention-deficit/hyperactivity disorder, and addiction. Methodological challenges include: performing genetic analyses in small study populations used in imaging studies; inclusion of patients with psychiatric comorbidities; and the extensive variability across studies in neuroimaging protocols, neurobehavioral task probes, and analytic strategies. Moreover, few studies use pharmacogenetic designs that permit testing of genotype × drug effects. As a result of these limitations, few findings have been fully replicated. Future studies that pre-screen participants for genetic variants selected a priori based on drug metabolism and targets have the greatest potential to advance the science and practice of psychiatric treatment.

PubMed Disclaimer

References

    1. Alexopoulos GS, Glatt CE, Hoptman MJ, Kanellopoulos D, Murphy CF, Kelly RE, Jr, et al. BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression. J Affect Disord. 2010;125:262–268. -PMC -PubMed
    1. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacol. 2007;32:1011–1020. -PubMed
    1. Arnone D, McKie S, Elliott R, Thomas EJ, Downey D, Juhasz G, et al. Increased amygdala responses to sad but not fearful faces in major depression: relation to mood state and pharmacological treatment. Am J Psychiatr. 2012;169:841–850. -PubMed
    1. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem. 1995;65:1157–1165. -PubMed
    1. Ashare RL, Falcone M, Lerman C.2013Cognitive function during nicotine withdrawal: implications for nicotine dependence Neuropharmacologyepub ahead of print 29 April 2013. doi: 10.1016/j.neuropharm.2013.04.034 -DOI -PMC -PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources